- Home
- MYSE vs QNRX Comparison
MYSE vs QNRX Comparison
Compare MYSE & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYSE | QNRX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 10.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYSE | QNRX |
|---|---|---|
| Price | $1.86 | $8.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.9K | 31.1K |
| Earning Date | 11-13-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $581.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.82 | N/A |
| 52 Week Low | $1.60 | $5.01 |
| 52 Week High | $5.93 | $41.80 |
Technical Indicators
Market Signals| Indicator | MYSE | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 39.84 |
| Support Level | $1.60 | $7.13 |
| Resistance Level | $2.05 | $8.01 |
| Average True Range (ATR) | 0.15 | 0.84 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 55.56 | 33.08 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.